Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Primary biliary cholangitis


Other Names for this Disease
  • PBC
  • Familial primary biliary cirrhosis
  • Primary Biliary Cirrhosis
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

Newline Maker

How might primary biliary cholangitis be treated?

Ursodiol is the drug approved by the FDA for the treatment of primary biliary  cholangitis.[1]

For more information on treatment of primary biliary cholangitis with Ursodiol, please visit the following link from PBCers Organization, a nonprofit organization that supports primary biliary  cholangitis. http://www.pbcers.org/about-pbc/ursodiol.php
Last updated: 1/22/2016

References
  1. Ursodiol Treatments. PBCers. 1/18/2014; http://www.pbcers.org/about-pbc/ursodiol.php.


Clinical Trials & Research for this Disease

  • The Centers for Mendelian Genomics program is working to discover the causes of rare genetic disorders. For more information about applying to the research study, please visit their website.
  • ClinicalTrials.gov lists trials that are studying or have studied Primary biliary cholangitis. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.
  • Orphanet lists European clinical trials, research studies, and patient registries enrolling people with this condition. 
  • The Research Portfolio Online Reporting Tool (RePORT) provides access to reports, data, and analyses of research activities at the National Institutes of Health (NIH), including information on NIH expenditures and the results of NIH-supported research. Although these projects may not conduct studies on humans, you may want to contact the investigators to learn more. To search for studies, enter the disease name in the "Text Search" box. Then click "Submit Query".

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name obeticholic acid
Trade Name
(Manufacturer Name)
Ocaliva
(Intercept Pharmaceuticals, Inc)
Indication
The FDA has approved this product to be used in this manner.
Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
More Information about this product Drug Information Portal

Generic Name Ursodiol
Trade Name
(Manufacturer Name)
Urso 250
(Aptalis Pharma US, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with primary biliary cirrhosis
More Information about this product Drug Information Portal
Medline Plus Health Information

Other Names for this Disease
  • PBC
  • Familial primary biliary cirrhosis
  • Primary Biliary Cirrhosis
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.